Dr. Franziska Münz | Medicine and Dentistry | Future Science Leader Award
100
75
50
25
0
97
10
5
100
75
50
25
0
Medical Oncologist at Hospital 12 de Octubre | Spain
Baena Espinar, J. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials: Pembro-real 5Y registry results. Journal for Immunotherapy of Cancer.
Baena Espinar, J., et al. (2025). Clinical utility of combined tissue and plasma next-generation sequencing in treatment-naïve advanced NSCLC. JTO Clinical and Research Reports.
Baena Espinar, J., et al. (2025). Efficacy and safety of lorlatinib in ALK- and ROS1-rearranged metastatic NSCLC within the compassionate use program in Spain.
Baena Espinar, J., et al. (2025). Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in lung cancer patients.
Baena Espinar, J., et al. (2025). Safety and efficacy of immune checkpoint therapy in patients with cardiac metastasis: A multicenter international retrospective analysis.
Baena Espinar, J., et al. (2025). Unmet needs in maintenance therapy for extensive-stage small cell lung cancer.
Baena Espinar, J. (2024). Consolidation osimertinib vs durvalumab vs observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of Thoracic Oncology.
Baena Espinar, J.(2024). Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical Cancer Research.
Baena Espinar, J.(2024). Real-world data of first-line cemiplimab monotherapy for PD-L1 high NSCLC. Journal of Thoracic Oncology.
Baena Espinar, J.(2024). Multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage SCLC. Clinical Cancer Research.
Baena Espinar, J.(2024). Targeting KRAS G12C in NSCLC: Current standards and developments. Drugs.
Baena Espinar, J.(2023). Future perspectives in second-line therapy for non-oncogene–addicted NSCLC. Cancers.
Baena Espinar, J. (2023). Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer. Journal of Clinical Oncology.
Baena Espinar, J.(2022). Updated prognostication system for thoracic malignancies with COVID-19: TERAVOLT registry. Journal of Thoracic Oncology.
Baena Espinar, J. (2022). COVID-19 outcomes, vaccination status, and cancer-related delays during the Omicron wave: TERAVOLT analysis. JTO Clinical and Research Reports.